Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma
NCT01034787
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
11
Enrollment
OTHER
Sponsor class
Conditions
Uveal Melanoma
Interventions
DRUG:
CP-675,206
Sponsor
AHS Cancer Control Alberta